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rity (42%), patient confirmation accuracy (73%), the correct rate of administration 
time (47%) and the correct rate of drug administration (57%). More than half of 
pharmacists and nurses complain the system wasn’t stable (53%, 69%) and poor bar-
code sensitivity (47%, 64%). The ratio of medication error was significantly reduced. 
(0.18%±0.042%, 0.12%±0.039%, P value < 0.05, n= 12) From Oct 2nd to Nov 15th in 2012, 
we received 469 phone calls. The average of tracing call for drugs is 1.67 times every 
hour. ConClusions: Though some system problems may annoy hospital staffs, 
BCMA system could increase the accuracy of recognizing drugs, patients and tracing 
drugs. BCMA system also could significantly improve patient safety.
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external referenCe PriCing (erP) in tUrkey and its effeCts on 
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objeCtives: ERP is the practice of using pharmaceutical prices in several countries 
to derive a price benchmark in a given country and could be used as the main 
criteria for pricing decisions or merely as supportive information. It is a widely 
used financing method worldwide and in Europe; by 2012, all EU-countries except 
UK and Sweden used ERP in some form. Turkey applies ERP as the main pricing 
criteria since 2004. This analysis aims to elaborate the Turkish ERP system with its 
effects on the countries referring Turkey. Methods: ERP systems of Turkey and 
countries referring Turkey have been analyzed. Results: Turkish reference basket 
is composed of Greece, Italy, France, Spain and Portugal, whose prices are rela-
tively lower than the European-average, plus import and manufacturer countries 
of the product. Lowest basket price sets the price-ceiling for reimbursed products, 
while highest can be taken for non-reimbursed products. Reference prices are sub-
ject to an exchange rate, fixed by Ministry of Health at approximately 40% below 
the actual rate. Consequently, Turkish prices are almost 44% of the lowest-priced 
European-country. Among the countries referring Turkey, Russia and S.Arabia are 
the most significant markets with their size and growing potentials. Additionally, 
Egypt, Macedonia, Morocco, Oman and Iran refer Turkey. ConClusions: Although 
countries referring Turkey have large reference baskets, low Turkish prices could still 
be considered as a suppressing factor on prices in these countries. Furthermore, 
significant price changes especially in Russia and S.Arabia would possibly cause 
a second wave in some CIS and Middle East countries respectively, as they would 
adjust their prices within 6-12 months accordingly. Multinational companies con-
sider this domino effect seriously and usually arrange launch sequencing to avoid 
inoperably-low-prices and secure the most-promising-markets. Consequently, 
innovative products’ price levels and availability might occasionally be affected 
negatively in Turkey and further in countries referring Turkey.
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objeCtives: In July 2012, the European Medicines Agency (EMA) established the 
Pharmacovigilance and Risk Assessment Committee (PRAC). The PRAC recommends 
and advises on any questions of pharmacovigilance activities related to a medi-
cine for human use and on risk management systems. This study describes PRAC’s 
activities to date. Methods: Meeting minutes since July 2012 were retrieved from 
the EMA website. The PRAC received questions attributed to seven categories: EU 
referral procedures for safety reasons, signals assessment and prioritization, risk 
management plans (RMPs), assessment of periodic safety update reports (PSURs), 
post-authorisation safety studies (PASS), product-related pharmacovigilance 
inspections, and other safety issues for discussion requested by the Committee 
for Medicinal Products for Human Use (CHMP) or Member States (MS). Results: 
There were 13 meeting minutes available (July 2012 – October 2013), containing1077 
questions/requests with/without a formal decision-making phase [149 (13.9%) in 
2012, 928 (86.2%) in 2013]. Three request types comprise nearly 80% (n= 860): signal 
assessment and prioritization [n= 140 (13%), 50 (4.7%) in 2012, 90 (8.4%) in 2013], 
RMPs [n= 416 (38.7%), 48 (4.5%) in 2012, 368 (34.2%) in 2013], and PSURs [n= 304 
(28.2%), 20 (1.8%) in 2012, 284 (26.4%) in 2013]. PRAC outputs were recommenda-
tions or advice. In 2012, there were 46 recommendations for 35 new signal assess-
ments requests. Recommendations regarding new signals were made either to the 
Marketing Authorization Holder (MAH) (n= 32) (e.g., submit a cumulative review of 
dermatomyositis within 30 days), the EMA (n= 6) (e.g., review cases of dermatomy-
ositis and report back), the PRAC rapporteur (n= 7) (e.g., assess the UK cases in the 
ongoing PSUR procedure) or the MS (n= 1) (e.g., UK to provide a report on the nicotinic 
receptor mutation). ConClusions: After an initial “running-in period”, the PRAC 
appears to be fulfilling its mandate. PRAC operations should be evaluated in terms 
of success (i.e., impact of decisions).
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objeCtives: This article makes a review on the historical evolution of China’s drug 
regulatory system and provides some reflections and policy implications for the 
reform of the present system. Methods: This study is based on literature review 
and publicly available data by searching electronic databases and official web pages 
of Chinese government on the internet. Results: China’s drug regulatory system 
has experienced complicated process of evolution. During the period of planned 
economy China had no independent drug regulatory system. The way to control 
the quality and safety of pharmaceutical products was to take full control of every 
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objeCtives: Medication oversupply is an important problem which causes unnec-
essary avoidable health care costs. There are some studies determining magnitude 
and financial loss due to medication oversupply in western countries, they may not 
be applicable for Asia-pacific countries. This study aims to determine the preva-
lence, financial loss, and patterns of medication oversupply and factors associated 
with oversupply in Thailand. Methods: A retrospective database analysis was 
conducted. Patients visiting out-patient department of 3 hospitals and receiving 
at least 2 prescriptions within 6 months were included. The modified medication 
possession ratio (MPRm) was used to determine the medication supply. Patients 
having MPRm> 1.20 were defined as medication oversupply. The measures were 
prevalence of medication oversupply, the number of oversupplied medications, 
and financial loss due to medication oversupply. Analyses were stratified by type 
of hospitals. A mixed regression model was used to determine factors associated 
with prevalence medication oversupply. Results: A total of 99,743 patients were 
included. Patients were on average 49.7±21.2 years of age, 42.8% were male. Around 
13.4% of all patients had medication oversupply. Patients in regional hospital had 
higher prevalence of medication oversupply than patients in district hospital (13.8% 
VS 8.2%). Patients under civil servant medical benefit schemes (CSMBS) (13.6%) 
had the highest prevalence of medication oversupply. The total financial loss due 
to medication oversupply was $189,024 per year. The average financial loss due 
to medication oversupply was $1.9±19.0 per patient/year. Patients under CSMBS 
was highest average financial loss (2.6±23.2 $/patient/year). Age, gender, health 
insurance schemes, and number of medications the patients received were factors 
associated with medication oversupply. ConClusions: Medication oversupply is 
an important problem for the health system. Patients receiving care from regional 
hospital had higher likelihood of medication oversupply. Policy-makers may con-
sider developing policies for preventing medication oversupply.
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objeCtives: The recent reforms and policy changes have increased the cost pres-
sures on all health care stakeholders, including clinical experts. In the past, clini-
cal guidelines were developed independent of cost or economic considerations. 
However, increasingly, more clinical guidelines are mentioning cost concerns and 
referring to economic data in new recommendations. The objective of this study was 
to analyze trends in the use of health economic information for developing clinical 
guidelines. Methods: To understand trends in use of health economic informa-
tion we conducted targeted search for clinical guidelines, expert recommendations, 
and consensus statements with specific mention of “cost” or “economic” or related 
terms. A systematic literature search was undertaken for the databases Pubmed, 
Google Scholar and Cochrane. The guidelines published between 2003-2012 were 
included. For guidelines which met the search criteria, data was collected for the 
name of the authors, indication, year of publication, country/region, and context 
of use of cost/economic evidence. Results: Sixteen clinical guidelines published 
between 2003-2012 met the inclusion criteria for specific mention of cost/economic 
evidence. More than 50% of these guidelines were published between 2006-2012. For 
indication, 3 out of 16 guidelines were for diabetes, while the rest were for different 
indications. In these 16 guidelines “cost effectiveness” was mentioned 14 times, 
either referencing cost-effectiveness data or to mention the importance of such data 
for selecting treatment options. The guidelines commonly cite high cost of disease 
or high economic burden as one of the considerations for developing new recom-
mendations (11 out of 16). Another term that was commonly used by these guide-
lines was “cost-benefit,” which was mentioned 5 times in these guidelines. Notably, 
QALY was rarely mentioned (1 out of 16 times) in these guidelines. ConClusions: 
This analysis suggests that some clinical experts groups are increasingly showing 
willingness to use and incorporate health economic information for developing 
new recommendations
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objeCtives: To analyze the current usage of BCMA enforced by the pharmacists 
and nurses at a medical center in Taiwan, we collected data including of the overall 
system satisfaction, ratio of medication errors and phone calls for tracking stat 
drugs. Methods: The overall system’s satisfaction questionnaire for nurse (n= 89) 
and pharmacist (n= 30) was designed by 8 experts using content validity index (CVI). 
We have collected medication error ratio for one year in order to evaluate patients’ 
safety before and after using BCMA system. We also collected the numbers of phone 
calls for tracking stat drugs during Oct 2nd to Nov 15th in 2012. Results: In phar-
macists’ satisfaction questionnaire, they agree BCMA system can help them rec-
ognize drugs (60%), reduce medication errors (53%) and check drug delivery (90%). 
But they also think BCMA has increased workload (57%). In nurses’ satisfaction 
questionnaire, they agree BCMA system can help them increase case data’s integ-
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objeCtives: Many initiatives (e.g., PROTECT, EFSPI) are exploring quantitative meth-
odologies to conduct benefit/risk assessments of medicines. Objectives of this study 
were to combine quantitative methodologies that can capture expert knowledge 
and decisionmakers insights to genuinely support real-world decisions. Methods: 
Using the case study of efalizumab, approved by the EMA in 2004 for the treatment 
of plaque psoriasis and withdrawn in 2009, a pragmatic methodology was developed 
that combines advanced pharmacoepidemiology and MCDA for quantitative benefit/
risk assessment. Development involved application of: MCDA principles to ensure 
applicability to any therapeutic area, comparability across medicines, and portabil-
ity over product cycle (re-evaluation); and advanced pharmacoepidemiology and 
Bayesian modeling to identify/generate most useful data. Overarching design was 
guided by ethical implications of criteria and data selection as well as applicability in 
real life settings including face validity, time constraints, complexity and transpar-
ency. Results: The hierarchical multicriteria model consists of two major domains: 
Benefits (favourable effects, covering the criteria Clinical efficacy/effectiveness and 
Patient Reported outcomes); and Risks (unfavourable effects – criterion Safety). The 
safety criterion is subdivided into three generic subcriteria (Adverse events, Serious 
AEs and Fatal AEs). The benefit criteria are subdivided into specific subcriteria that 
correspond to the most relevant outcomes for a treatment for plaque psoriasis. All 
performance are assigned relative to existing alternatives or placebo. Each subcri-
terion contributes to the output of the model, the Benefit/Risk Estimate, which is 
the sum of normalized weights for each subcriterion multiplied by the respective 
performance score. Pharmacoepidemiology data is provided in a standardized for-
mat for each subcriterion and includes meta-analytic comparative statistics based 
on clinical trials, observational data and Bayesian models. Uncertainty is explored 
in sensitivity analyses. ConClusions: Integration of pragmatic MCDA modeling 
with advanced pharmacoepidemiology allows quantitative benefit/risk assessment 
that can be applicable and meaningful in real life regulatory settings.
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objeCtives: The Center for Translational Molecular Medicine (CTMM) is a multi-
million public-private partnership, including universities, academic hospitals, phar-
maceutical and medical technology companies. CTMM aims to accelerate molecular 
diagnostics and imaging technologies to enable determination of predisposition, 
early diagnosis, and personalized treatment of patients. It is unique in that it man-
dates early Health Technology Assessment (HTA) in each of its 21 projects. This study 
assessed the impact of CTMM on scientific, translational, clinical and economic 
aspects. Methods: The impact assessment was guided by the “Research Impact 
Framework” (Kuruvilla 2006) Objective data were gathered from extensive CTMM 
administrations, including publications, patents, project proceedings, early HTA 
results, etc. Perceived impact was investigated using a CTMM-wide survey (n= 167) 
and two focus groups. Results: CTMM focuses its impact on disease areas with 
high Disability Adjusted Life Years and high societal costs, i.e. oncology, cardiovas-
cular, neurologic, infection and immunity diseases. Its scientific impact is as high 
as the overall impact of Dutch biomedical research, i.e. 15%-80% above international 
volume and journal impact standards. CTMM is perceived to stimulate and acceler-
ate translation of technology to the clinic, with a median score of 4 out of 5 (IQR 
3-5). Its main strength lies in pre-clinical and phase 1 development (median score 
4 of 5; IQR 4-5). CTMM has generated nearly 1900 FTE of translational R&D capacity 
between 2008-15. Experience with and impact of early HTA varies widely between 
projects (median score 3 of 5; IQR: 2-4). CONCLUSION: By facilitating and managing 
effective and safe public-private collaboration, CTMM has demonstrated a solid sci-
entific impact. Its impact on translational, (future) clinical and economic aspects is 
generally perceived as large. Metrics to objectively measure this need improvement 
as well as longer follow-up. The early HTA analyses have provided critical insights 
and exemplar approaches for future early HTA work in public-private partnerships.
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objeCtives: In 2011 was published 12.401 Law establishing the National Committee 
for Technologies Incorporation in SUS (CONITEC) and defining the criteria and dead-
lines for the analysis and adoption of technologies. According to the law, CONITEC’s 
assessment must considers necessarily scientific evidences about efficacy, accuracy, 
effectiveness and safety of technologies and economic evaluation studies of ben-
efits and costs in relation to the technologies already incorporated in SUS. Studies 
of economic evaluation traditionally ignore equity in health, and because this gap, 
researches have been undertaken to develop methods to incorporate equity into 
economic evaluation in health. Thus, this paper aims to analyze the viability of 
using an economic evaluation framework in the decision making process about 
incorporating technologies so that the equity is maximized within the Brazilian 
Unified Health System. Methods: To fulfill this goal, review the scientific lit-
erature for methods to incorporate equity into cost-effectiveness was conducted 
with subsequent discussion how the methods found can be applied in the con-
text of SUS, a system that offers universal coverage to approximately 201 million 
citizens. Results: Until end of 2013, CONITEC recommended the incorporation of 
64 technologies for diagnosis, prevention and treatment of various diseases, and 
no study of economic evaluation submitted addressed the issue of equity. By the 
research found a systematic review conducted by Johri & Norheim (2012) having 
found three distinct approaches: integration of distributional concerns through 
equity weights and social welfare functions, exploration of the opportunity costs 
of alternative policy options, through mathematical programming and multi-cri-
aspect of the pharmaceutical industry. After the reform policy in 1978, both the 
governmental regulators and the regulated pharmaceutical industry became devel-
opment-oriented. The effective control of the quality and safety of pharmaceutical 
products became a serious problem. In order to reverse the situation China tried 
to establish an independent drug regulatory system. ConClusions: Because of 
path dependence it is very difficult to turn the drug regulatory system from the sys-
tem of unification of the regulators and the regulated into an independent system. 
The introduction of a formally independent regulatory system has improved the 
regulator’s motive to supervise the quality and safety of drugs to some extent. But 
many impediment factors still exist both inside and outside China’s drug regula-
tory system. The great difficulties to establish an effective drug regulatory system 
China experienced during the past 10 years proved that the old way in which the 
government regulatory agencies operate is very difficult to shake. The policy maker 
should fully understand the impact of the previous system and make a long and 
Coordinative effort. The best way to establish a good independent drug regulatory 
system has to be a gradual rather than a radical reform.
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objeCtives: The Brazilian Public Health System (SUS) was established in 1988, 
thereby ensuring that the citizen universal right to health, having as one of its 
principles to the participation or social control. The performance of the SUS in the 
field of evaluation and incorporation of new technologies represents the public 
interest as defined by universal policies are committed to the equity and based on 
scientific knowledge consistent. The year of 2011 represented a breakthrough in 
transparency and social participation in the process of incorporating technology 
with the publication of Law no. 12,401, of 28/04/2011, which has set up a National 
Commission for the Incorporation of Technology in the SUS/CONITEC. The aim of 
this study was to identify in the participation of public consultations of CONITEC, 
the civil society participation, public and private institutions. Methods: This is a 
descriptive, cross-sectional study, which was developed from the analysis of tech-
nical reports of Conitec which related to public consultation by the committee 
were extracted data to support decision-making on technology incorporation in 
SUS. Results: In the years 2012 and 2013, 78 public consultations and more than 
4,182 contributions were examined by CONITEC published arising from health care 
institutions, patient association, educational institutions, medical societies, etc, that 
recommended to incorporate 64 new technologies in the SUS. ConClusions: The 
Ministry of Health, responsible for enforcement of the law n. 12.401, use system-
atically the public consultations as the instrument to gather contributions from 
segments of society in their process work. To the extent that such participation 
is intended to subsidize the decision about incorporating technology in the SUS, 
there are significant gains in building the public policy agenda, adding legitimacy 
and transparency in government decision-making.
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objeCtives: The Brazilian public health system ensures universal, equitable and 
comprehensive access to health technologies, including medicines. The high-cost 
medicines are offered through Specialized Pharmaceutical Services Component 
(SPSC). The clinical conditions treated in the SPSC are defined in the Guidelines in 
the form of lines of care. To describe the experience and results of the SPSC with its 
particular strategies in the quest for the comprehensive health care. Methods: 
Focused on the SPSC’s issues, we did a retrospective data analysis related to its 
management strategies for the pharmaceutical services in the public health sys-
tem in the period 2010 to 2013. Data were obtained from documents of the Ministry 
of Health in 2013 (current values; exchange rate: US$ 1 = R$ 2.30). Results: As 
a strategy to increase medicines access and optimization of resource allocation, 
the MoH expanded the amount of centralized procurement medicines, from 13 
to 51 products. This deed was focused on those medicines with a concentrated 
market. As a consequence, this action allowed a saving of U$ 403.8 million in four 
years, compared to the price in 2010. The medicines that most contributed to the 
economy were adalimumabe (U$120 million), etanercepte (U$100 million) and 
infliximab (U$44 million). Betainterferona (52%), etanercepte (48%), imiglucerase 
(48%), adalimumabe (37%) e Alfapeginterferona (37%) were the products with a 
greater reduction in the unit price, considering the accumulated value at period. 
The increase in the number of units distributed was 263%. ConClusions: The 
SPSC was designed in 2010 for the budgetary resources optimization and to expand 
access to medicines for diseases that require complex health services or high-cost 
medicines. The purchasing power of the MoH is a strategy that allowed expansion 
of access to medicines, with optimization of budgetary resources in the Brazilian 
public health system.
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